{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:08:34Z","timestamp":1749625714815},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Pr\u00edncipe de Asturias","award":["FIB-PI13-04"],"award-info":[{"award-number":["FIB-PI13-04"]}]},{"DOI":"10.13039\/501100006302","name":"University of Alcal\u00e1","doi-asserted-by":"crossref","award":["CCG2014\/BIO-028"],"award-info":[{"award-number":["CCG2014\/BIO-028"]}],"id":[{"id":"10.13039\/501100006302","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Research Service of the Veterans Affairs Department"},{"DOI":"10.13039\/100006686","name":"University of Miami","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.peptides.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:16:52Z","timestamp":1478132212000},"page":"153-161","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells"],"prefix":"10.1016","volume":"86","author":[{"given":"Eva","family":"Vacas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mu\u00f1oz-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew V.","family":"Schally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Carmena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Bajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0005","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.peptides.2016.11.004_bib0010","first-page":"25","article-title":"A review of systemic treatment in metastatic triple-negative breast cancer","volume":"10","author":"Zeichner","year":"2016","journal-title":"Breast Cancer (Auckl.)"},{"issue":"10","key":"10.1016\/j.peptides.2016.11.004_bib0015","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/bjc.2013.144","article-title":"Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers","volume":"108","author":"Lips","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.peptides.2016.11.004_bib0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/bjc.2014.444","article-title":"Predicting response and survival in chemotherapy-treated triple-negative breast cancer","volume":"111","author":"Prat","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.peptides.2016.11.004_bib0030","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"36","key":"10.1016\/j.peptides.2016.11.004_bib0035","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.peptides.2016.11.004_bib0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-7-134","article-title":"Use of immunohistochemical markers can refine prognosis in triple negative breast cancer","volume":"7","author":"Tischkowitz","year":"2007","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.peptides.2016.11.004_bib0045","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1073\/pnas.0700407104","article-title":"Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor","volume":"104","author":"Barabutis","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.peptides.2016.11.004_bib0050","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/sj.bjc.6604386","article-title":"Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines","volume":"98","author":"Barabutis","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ncpendmet0677","article-title":"Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer","volume":"4","author":"Schally","year":"2008","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"48","key":"10.1016\/j.peptides.2016.11.004_bib0060","doi-asserted-by":"crossref","first-page":"17424","DOI":"10.1073\/pnas.0506844102","article-title":"The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues","volume":"102","author":"Havt","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3892\/or.2013.2435","article-title":"Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers","volume":"30","author":"Seitz","year":"2013","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.peptides.2016.11.004_bib0070","first-page":"1025","article-title":"The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines","volume":"39","author":"Pozsgai","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"6764","key":"10.1016\/j.peptides.2016.11.004_bib0075","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/47260","article-title":"EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF","volume":"402","author":"Prenzel","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0080","first-page":"120","article-title":"The complexity of targeting EGFR signalling in cancer: from expression to turnover","volume":"1766","author":"Sebastian","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.peptides.2016.11.004_bib0085","doi-asserted-by":"crossref","first-page":"e44368","DOI":"10.1371\/journal.pone.0044368","article-title":"Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer","volume":"7","author":"Kuzumaki","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.peptides.2016.11.004_bib0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.tips.2007.09.007","article-title":"GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation","volume":"28","author":"Delcourt","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.peptides.2016.11.004_bib0095","first-page":"1223","article-title":"Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: antagonistic action of an analog of growth-hormone-releasing hormone","volume":"31","author":"Sotomayor","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.peptides.2016.11.004_bib0100","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ijc.25192","article-title":"Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095)","volume":"127","author":"Sotomayor","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.peptides.2016.11.004_bib0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.mce.2010.04.008","article-title":"EGF receptor activation by GPCRs: an universal pathway reveals different versions","volume":"331","author":"Liebmann","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"issue":"15","key":"10.1016\/j.peptides.2016.11.004_bib0110","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1074\/jbc.273.15.8890","article-title":"Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells","volume":"273","author":"Eguchi","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.peptides.2016.11.004_bib0115","doi-asserted-by":"crossref","first-page":"19700","DOI":"10.3390\/ijms151119700","article-title":"Cell-surface receptors transactivation mediated by g protein-coupled receptors","volume":"15","author":"Cattaneo","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.peptides.2016.11.004_bib0120","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ijc.2910460427","article-title":"Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype","volume":"46","author":"Valverius","year":"1990","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2008.11.024","article-title":"Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells","volume":"302","author":"Valdehita","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.peptides.2016.11.004_bib0130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/1535-7163.MCT-04-0280","article-title":"Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells","volume":"4","author":"Xu","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.peptides.2016.11.004_bib0135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10637-014-0131-4","article-title":"Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models","volume":"32","author":"Munoz-Moreno","year":"2014","journal-title":"Invest. New Drugs"},{"issue":"3","key":"10.1016\/j.peptides.2016.11.004_bib0140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/membranes4030424","article-title":"The mysterious ways of ErbB2\/HER2 trafficking","volume":"4","author":"Bertelsen","year":"2014","journal-title":"Membranes (Basel)"},{"issue":"7","key":"10.1016\/j.peptides.2016.11.004_bib0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0196-9781(99)00071-6","article-title":"Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro","volume":"20","author":"Csernus","year":"1999","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.peptides.2016.11.004_bib0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1677\/joe.0.1630269","article-title":"Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro","volume":"163","author":"Csernus","year":"1999","journal-title":"J. Endocrinol."},{"issue":"10","key":"10.1016\/j.peptides.2016.11.004_bib0155","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1043-2760(02)00634-3","article-title":"Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling","volume":"13","author":"Driggers","year":"2002","journal-title":"Trends Endocrinol. Metab."},{"issue":"18","key":"10.1016\/j.peptides.2016.11.004_bib0160","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/0008-5472.CAN-12-1803","article-title":"SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.peptides.2016.11.004_bib0165","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","article-title":"Targeting Src in breast cancer","volume":"19","author":"Finn","year":"2008","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.peptides.2016.11.004_bib0170","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jcp.21246","article-title":"Mitogenic signaling pathways induced by G protein-coupled receptors","volume":"213","author":"Rozengurt","year":"2007","journal-title":"J. Cell. Physiol."},{"issue":"10","key":"10.1016\/j.peptides.2016.11.004_bib0175","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cellsig.2010.05.012","article-title":"Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation","volume":"22","author":"El Zein","year":"2010","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.peptides.2016.11.004_bib0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jb\/mvr068","article-title":"Ectodomain shedding and remnant peptide signalling of EGFRs and their ligands","volume":"150","author":"Higashiyama","year":"2011","journal-title":"J. Biochem."},{"issue":"12","key":"10.1016\/j.peptides.2016.11.004_bib0185","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/bjc.2015.163","article-title":"Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells","volume":"112","author":"Caiazza","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.peptides.2016.11.004_bib0190","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4161\/cbt.8.11.8539","article-title":"ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation","volume":"8","author":"Zheng","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.peptides.2016.11.004_bib0195","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","article-title":"The ADAM metalloproteinases","volume":"29","author":"Edwards","year":"2008","journal-title":"Mol. Aspects Med."},{"issue":"5","key":"10.1016\/j.peptides.2016.11.004_bib0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/onc.2010.443","article-title":"A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17","volume":"30","author":"Maretzky","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.peptides.2016.11.004_bib0205","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1042\/bst0311203","article-title":"EGFR signal transactivation in cancer cells","volume":"31","author":"Fischer","year":"2003","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.peptides.2016.11.004_bib0210","first-page":"1285","article-title":"Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines","volume":"36","author":"Barabutis","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.peptides.2016.11.004_bib0215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.27716","article-title":"Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer","volume":"132","author":"Mu\u00f1oz-Moreno","year":"2013","journal-title":"Int. J. Cancer"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978116302170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978116302170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T03:28:55Z","timestamp":1657596535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978116302170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":43,"alternative-id":["S0196978116302170"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2016.11.004","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}